Iryna Drozd/iStock via Getty Images Theriva Biologics ( NYSE: TOVX ) said it has received FDA fast track designation for its drug VCN-01 in the treatment of metastatic pancreatic cancer. The status was granted for the drug’s use in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma. VCN-01, Theriva’s lead drug candidate, also has FDA fast track status for the treatment of pancreatic ductal adenocarcinoma.

More on Theriva Biologics Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Theriva Biologics Historical earnings data for Theriva Biologics Financial information for Theriva Biologics.